KR102628892B1 - 인간 sting의 소분자 조절제 - Google Patents

인간 sting의 소분자 조절제 Download PDF

Info

Publication number
KR102628892B1
KR102628892B1 KR1020207001712A KR20207001712A KR102628892B1 KR 102628892 B1 KR102628892 B1 KR 102628892B1 KR 1020207001712 A KR1020207001712 A KR 1020207001712A KR 20207001712 A KR20207001712 A KR 20207001712A KR 102628892 B1 KR102628892 B1 KR 102628892B1
Authority
KR
South Korea
Prior art keywords
oxo
carboxamide
trifluorobenzyl
methyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207001712A
Other languages
English (en)
Korean (ko)
Other versions
KR20200031616A (ko
Inventor
모나리 바네르지
산디프 미디아
수라브 바수
라지브 고쉬
데이비드 프라이드
다멘드라 야다브
리테쉬 슈리바스타바
아르준 수리야
Original Assignee
큐라데브 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1709959.9A external-priority patent/GB2563642A/en
Application filed by 큐라데브 파마 리미티드 filed Critical 큐라데브 파마 리미티드
Publication of KR20200031616A publication Critical patent/KR20200031616A/ko
Application granted granted Critical
Publication of KR102628892B1 publication Critical patent/KR102628892B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020207001712A 2017-06-22 2018-06-21 인간 sting의 소분자 조절제 Active KR102628892B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201711021858 2017-06-22
GB1709959.9 2017-06-22
GB1709959.9A GB2563642A (en) 2017-06-22 2017-06-22 Small molecule modulators of human STING
IN201711021858 2017-06-22
IN201811014462 2018-04-16
IN201811014462 2018-04-16
PCT/GB2018/051730 WO2018234808A1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting

Publications (2)

Publication Number Publication Date
KR20200031616A KR20200031616A (ko) 2020-03-24
KR102628892B1 true KR102628892B1 (ko) 2024-01-24

Family

ID=62816874

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207001712A Active KR102628892B1 (ko) 2017-06-22 2018-06-21 인간 sting의 소분자 조절제

Country Status (20)

Country Link
US (1) US11571423B2 (enExample)
EP (1) EP3642198B1 (enExample)
JP (1) JP7296954B2 (enExample)
KR (1) KR102628892B1 (enExample)
CN (1) CN111132972B (enExample)
AR (1) AR114975A1 (enExample)
AU (1) AU2018288018C1 (enExample)
CA (1) CA3067257A1 (enExample)
CL (1) CL2019003793A1 (enExample)
CO (1) CO2020000562A2 (enExample)
EC (1) ECSP20004580A (enExample)
IL (1) IL271522B2 (enExample)
MX (1) MX2019015468A (enExample)
PE (1) PE20200696A1 (enExample)
PH (1) PH12019502870A1 (enExample)
SG (1) SG11201912397RA (enExample)
TW (1) TWI799426B (enExample)
UA (1) UA125730C2 (enExample)
WO (1) WO2018234808A1 (enExample)
ZA (1) ZA201908496B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI689514B (zh) 2016-07-06 2020-04-01 美商史貝羅威生物科學有限公司 化合物、組合物及用於治療疾病之方法
GB2574913A (en) * 2017-06-22 2019-12-25 Curadev Pharma Ltd Small molecule modulators of human STING, conjugates and therapeutic applications
TWI799426B (zh) 2017-06-22 2023-04-21 英商克拉德夫製藥有限公司 人類ｓｔｉｎｇ之小分子調節劑
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
EP3946610A1 (en) 2019-03-28 2022-02-09 Lupin Limited Macrocyclic compounds as sting agonists
JP7531508B2 (ja) * 2019-04-30 2024-08-09 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド ベンゾチオフェン化合物、その調製方法およびその使用
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
KR102812984B1 (ko) * 2019-06-12 2025-05-26 리부 세라퓨틱스 에스.에이. 인터페론 유전자 자극인자(sting)의 차세대 조절제
JP2022536755A (ja) * 2019-06-14 2022-08-18 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN114340680A (zh) 2019-07-05 2022-04-12 坦博公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
MX420195B (es) 2019-07-22 2025-02-10 Lupin Ltd Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
CN114728946A (zh) * 2019-09-25 2022-07-08 辉瑞公司 Sting (干扰素基因刺激剂)的多杂环调节剂
AU2020409429A1 (en) 2019-12-18 2022-06-16 Ctxt Pty Ltd Compounds
JP2023513241A (ja) * 2020-02-12 2023-03-30 キュラデブ ファーマ ピーブイティー． リミテッド 小分子ｓｔｉｎｇアンタゴニスト
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
EP4136076A1 (en) * 2020-04-16 2023-02-22 F. Hoffmann-La Roche AG Biphenyl derivatives
AU2021270750B2 (en) 2020-05-13 2024-06-13 Massachusetts Institute Of Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
WO2022169921A1 (en) * 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN117321055A (zh) * 2021-03-18 2023-12-29 辉瑞公司 Sting(干扰素基因刺激剂)的调节剂
WO2023017451A1 (en) 2021-08-11 2023-02-16 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
KR20240046553A (ko) * 2021-08-11 2024-04-09 큐라데브 파마 프라이버트 리미티드 Sting 길항제로서의 소분자 우레아 유도체
EP4530282A1 (en) * 2022-04-28 2025-04-02 Sds Biotech K.K. Haloalkyl sulfone anilide compound and herbicide containing same
CN115015310B (zh) * 2022-05-23 2024-12-10 宁波大学 一种巯基化合物的分析方法
CN114805309A (zh) * 2022-06-07 2022-07-29 中国药科大学 苯并杂环类化合物及其制备方法、药物组合物和应用
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof
CN119330982A (zh) * 2023-07-19 2025-01-21 中国科学院上海药物研究所 氮杂环丁烷类化合物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543866A (ja) * 2010-11-12 2013-12-09 デューク ユニバーシティ 熱ショック転写因子活性化化合物及びそのターゲットに関連する組成物及び方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HUP0101484A3 (en) 1998-03-31 2003-02-28 Warner Lambert Co Quinolones as serine protease inhibitors and medicaments containing them
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
US7417052B2 (en) 2004-09-29 2008-08-26 Sankyo Company, Limited Phenylene derivative having tetrazole ring or thiazolidinedione ring
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
CA2656507C (en) * 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
TW200831498A (en) 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
AU2008254585B2 (en) 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
EP2723717A2 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
JP2016147807A (ja) 2013-06-04 2016-08-18 日本理化学工業株式会社 ヒドロキサム酸誘導体またはその塩
EP3193600A4 (en) 2014-09-10 2018-05-23 Epizyme, Inc. Smyd inhibitors
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
US20170146519A1 (en) 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
GB2572526A (en) * 2017-06-22 2019-10-09 Curadev Pharma Ltd Heterocyclic small molecule modulators of human STING
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
TWI799426B (zh) 2017-06-22 2023-04-21 英商克拉德夫製藥有限公司 人類ｓｔｉｎｇ之小分子調節劑
GB2563642A (en) 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543866A (ja) * 2010-11-12 2013-12-09 デューク ユニバーシティ 熱ショック転写因子活性化化合物及びそのターゲットに関連する組成物及び方法

Also Published As

Publication number Publication date
IL271522A (en) 2020-02-27
IL271522B1 (en) 2023-03-01
EP3642198B1 (en) 2022-03-16
PH12019502870A1 (en) 2020-09-28
CA3067257A1 (en) 2018-12-27
PE20200696A1 (es) 2020-06-16
KR20200031616A (ko) 2020-03-24
JP7296954B2 (ja) 2023-06-23
WO2018234808A1 (en) 2018-12-27
MX2019015468A (es) 2020-08-03
CL2019003793A1 (es) 2020-08-07
IL271522B2 (en) 2023-07-01
CN111132972B (zh) 2024-07-12
AR114975A1 (es) 2020-11-11
SG11201912397RA (en) 2020-01-30
US20200147083A1 (en) 2020-05-14
AU2018288018A1 (en) 2020-01-16
CO2020000562A2 (es) 2020-01-31
CN111132972A (zh) 2020-05-08
TW201920120A (zh) 2019-06-01
ZA201908496B (en) 2021-04-28
US11571423B2 (en) 2023-02-07
ECSP20004580A (es) 2020-05-29
AU2018288018B2 (en) 2022-04-14
EP3642198A1 (en) 2020-04-29
JP2020524719A (ja) 2020-08-20
BR112019027127A2 (pt) 2020-07-07
UA125730C2 (uk) 2022-05-25
AU2018288018C1 (en) 2022-10-20
TWI799426B (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
KR102628892B1 (ko) 인간 sting의 소분자 조절제
US20200172483A1 (en) Heterocyclic small molecule modulators of human sting
US20200138827A1 (en) Small molecule modulators of human sting
US11858918B2 (en) GLP-1R modulating compounds
CN106715415B (zh) 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮
WO2019243823A1 (en) Azaheterocyclic small molecule modulators of human sting
GB2563642A (en) Small molecule modulators of human STING
JP7691974B2 (ja) アセチル補酵素ａシンテターゼ短鎖２（ａｃｓｓ２）の小分子阻害剤
GB2572526A (en) Heterocyclic small molecule modulators of human STING
GB2574862A (en) Azaheterocyclic small molecule modulators of human STING
HK40029530A (en) Small molecule modulators of human sting
HK40029530B (en) Small molecule modulators of human sting
BR112019027127B1 (pt) Compostos moduladores de sting humano de molécula pequena, composição farmacêutica, usos dos mesmos e conjugado
EA041968B1 (ru) Низкомолекулярные модуляторы sting человека

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200117

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210603

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230302

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230908

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230302

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230908

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230427

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210603

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200219

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20231222

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231207

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230908

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230427

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210603

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200219

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240119

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240119

End annual number: 3

Start annual number: 1

PG1601 Publication of registration